27.07.2006 – 14:01

Zeltia Group

Zeltia S.A.: Report at 30 June 2006

Madrid, Spain (ots/PRNewswire)

Corporate:

• Zeltia performs 1-for-50 bonus issue
• Group revenues amounted to 42.5 million euro.
• Investment in R&D amounted to 24.4 million euro in the first half of 2006.
• The net cash position (cash + cash equivalents + current financial assets - short-term borrowings) amounted to 55.3 million euro.

PharmaMar:

- Excellent results of Yondelis in myxoid liposarcomas and ovarian
carcinoma presented at ASCO 2006

NeuroPharma:

- Progress with its first clinical-phase compound

Zelnova:

- Entered the Italian market by acquiring Copyr

Isabel Lozano     Catherine Moukheibir M(a) Luisa de Francia
    Chief Executive   Head of Capital      Chief Financial Officer
    Officer           Market Strategy
                                           ZELTIA, S.A.
    PHARMAMAR, S.A.   ZELTIA, S.A.
                                           José Abascal, 2. Madrid
    C/ Reyes, 1.      José Abascal, 2.
    Colmenar Viejo    Madrid               Telephone +34-91-444-45-00
    Madrid            Telephone
                      +34-91-444-45-00
    Telephone
    +34-91-846-60-00

For a copy of the full results, please refer to www.zeltia.com

Contact:

Isabel Lozano, Chief Executive Officer, PHARMAMAR, S.A., C/Reyes, 1.
Colmenar Viejo, Madrid, Telephone +34-91-846-60-00, Catherine
Moukheibir, Head of Capital Market Strategy, ZELTIA, S.A., José
Abascal, 2. Madrid, Telephone +34-91-444-45-00, M(a) Luisa de
Francia, Chief Financial Officer, ZELTIA, S.A., José Abascal, 2.
Madrid, Telephone +34-91-444-45-00